Objective The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and The International Committee of Radiological Protection and the International Atomic Energy Agency recommend establishing diagnostic reference levels (DRLs) as tools for dose optimization. Therefore, the development of DRLs based on the latest survey has been required for nuclear medicine-related societies and organizations. This prompted us to conduct a nationwide survey on the actual administered radioactivity to adults for the purpose of developing DRLs in nuclear medicine. Methods A nationwide survey was conducted from November 25, 2014 to January 16, 2015. The questionnaire was sent to all of the 1249 nuclear medicine facilities in Japan, and the responses were collected on a website using an answered form. Tc-MIBI), etc. were within the range of the EU DRLs and almost none of the administered radioactivity in Japan exceeded the upper limit of SNMMI standard administered radioactivity. Conclusions This survey indicated that the administered radioactivity in diagnostic nuclear medicine in Japan had been in the convergence zone and nuclear medicine facilities in Japan show a strong tendency to adhere to the texts and guidelines. Furthermore, the administered radioactivities in Japan were within the range of variation of the EU and the SNMMI administered radioactivities.
Results Responses were obtained from 516 facilities, for a response rate of 41 %. 75th percentile of 99m Tc-MDP and  99m Tc-HMDP: bone scintigraphy,  99m Tc-HM-PAO,  99m Tc-ECD and   123   I-IMP: cerebral blood flow scintigraphy,  99m Tc-Tetrofosmin,  99m Tc-MIBI and  201 Tl-Cl; myocardial  perfusion scintigraphy and 18 F-FDG: oncology PET (inhouse-produced or delivery) in representative diagnostic nuclear medicine scans were 932, 937, 763, 775, 200, 831, 818, 180, 235 and 252, respectively. More than 90 % of the facilities were within the range of 50 % from the median of these survey results in representative diagnostic nuclear medicine facilities in Japan. Responses of the administered radioactivities recommended by the package insert, texts and guidelines such as 740 MBq ( 99m Tc-MDP and 99m Tc-HMDP: bone scintigraphy), 740 MBq ( 99m Tc-ECD and 99m Tc-HM-PAO: cerebral blood flow scintigraphy) and 740 MBq ( 99m Tc-Tetrofosmin and 99m Tc-MIBI: myocardial perfusion scintigraphy), etc. were numerous. The administered activity of many radiopharmaceuticals of bone scintigraphy ( 99m Tc-MDP and 99m Tc-HMDP), cerebral blood flow scintigraphy ( 99m Tc-HM-PAO) and myocardial perfusion scintigraphy ( 99m Tc-Tetrofosmin and 99m Tc-MIBI), etc. were within the range of the EU DRLs and almost none of the administered radioactivity in Japan exceeded the upper limit of SNMMI standard administered radioactivity. Conclusions This survey indicated that the administered radioactivity in diagnostic nuclear medicine in Japan had been in the convergence zone and nuclear medicine facilities in Japan show a strong tendency to adhere to the texts and guidelines. Furthermore, the administered radioactivi
Introduction
The International Committee of Radiological Protection (ICRP) recommended three fundamental principles (justification, optimization of protection, and application of dose limits) for radiation protection. It should be noted that with regard to medical exposure of patients, it is not appropriate to apply dose limits or dose constraints, because such limits would often do more harm than good [1, 2] . Therefore, the justification and optimization of protection are very important in clinical practice. However, with the development of radiation medical technology increases in the medical exposure dose are of concern. The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and the ICRP and the International Atomic Energy Agency (IAEA) recommended establishing diagnostic reference levels (DRLs) as tools for dose optimization [3, 4] . In Europe, the European Union (EU) required establishment of DRLs by Council Directive 97/43/Euratom in 1996 [5] . It is suggested that DRLs should be set by countries, regions, academic societies or associations and they have been defined in Europe and North America [6] [7] [8] [9] [10] [11] [12] . On the other hand, in Japan the Japanese Society of Nuclear Medicine (JSNM) or other research groups have recommended the standard administration radioactivity dose [13, 14] . The Japan Association of Radiological Technologists (JART) recommended the reduction target dose [15, 16] and the JART conducted a nationwide survey of radiopharmaceutical doses [17] . Unfortunately this survey was not strictly limited to ''actual'' administered doses but included radioactivity doses determined by the time and date of assay of radiopharmaceuticals. Until 2015, neither a nationwide survey of ''actual'' administered doses had been conducted nor had DRLs been proposed by any nuclear medicine-related societies or organizations.
Concerning pediatric nuclear medicine, the European Association of Nuclear Medicine (EANM) dosage card has been proposed and developed by the Pediatric Task Group EANM in Europe [18] [19] [20] [21] and consensus guidelines have been proposed and developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in North America [22] [23] [24] [25] [26] . In 2014, the Japanese consensus guidelines for pediatric nuclear medicine were provided by JSNM in Japan [27] .
The Japan Network for Research and Information on Medical Exposures (J-RIME) was established in 2010 with the cooperation of related academic societies [28] . The J-RIME decided to establish the first DRLs (Japan DRLs) of common modality as all medical radiation-related societies and organizations at the annual meeting held in 2013. Therefore, the establishment of DRLs based on the latest survey results was required by nuclear medicine-related societies and organizations. This survey was performed voluntarily by medical radiation-related societies and organizations but was not forced by national offices.
The JSNM and JSNMT conducted a nationwide survey on the actual administered radioactivity in adults for the purpose of establishing DRL in nuclear medicine.
In Japan there is a unique system for delivered radiopharmaceuticals. When radiopharmaceuticals are provided from radiopharmaceutical manufacturers to nuclear medicine facilities, the radioactivity dose has been determined by the time and date of assay of radiopharmaceuticals. For example, in the case of 99m Tc and 123 I agents, the radiopharmaceutical to be delivered to the nuclear medicine facility has been assayed as the assay radioactivity (radioactivity at 12 am) of the delivery date (examination date). In addition, in the case of 201 Tl and 67 Ga agents, radioactivity in the two days after the delivery date is delivered (radioactivity at the delivery day is about 1.6 times the assay radioactivity). That is, the assay radioactivity does not actually mean the true administered radioactivity.
Methods
Distribution, collection, and contents of the questionnaire A nationwide survey on the actual administered radioactivity of adults for the purpose of providing DRLs in nuclear medicine was conducted from November 25, 2014 to January 16, 2015. The questionnaire was sent to all 1249 facilities where nuclear medicine examinations are performed in Japan, and the responses were sent to a website.
The questionnaire included items such as the average administered radioactivity dose of an adult for each diagnostic nuclear medicine examination, number of scanners, number of staff members, number of board certified nuclear medicine physicians and nuclear medicine radiological technicians.
How to calculate or evaluate the average administered radioactivity in each facility
The average administered radioactivity was obtained from the responses following this questionnaire.
1. The average value of the actually measured doses at the administered time or the average value of the assay dose that was corrected for the administered time. 2. The average administered radioactivity per week or the average administered radioactivity of several dozen times. 3. When the administered time is set at the facility, the average dose at that time. 4. The target administered radioactivity. 5. In the case of rare nuclear medicine examinations, the average administered radioactivity for several months or 1 year, or, the administered radioactivity in standard procedures. 6. For positron emission tomography (PET), the above 2 or 3 are used as a reference. The estimated radioactivity when using an automatic injecting machine for 18 F-FDG.
When calculating the average doses, responses that appeared clearly erroneous were excluded.
Results and discussion
Response rate and the distribution of administered radioactivity Replies were obtained from 516 facilities (response rate 41 %). The average, 75th, 80th and 90th percentile of each administered radioactivity are shown in Table 1 
Distribution of administered radioactivity in a representative diagnostic nuclear medicine examination
The administered radioactivity distributions of bone scintigraphy, cerebral blood flow scintigraphy, myocardial perfusion scintigraphy for single photon emission computed tomography (SPECT) and Figure 1 shows the administered radioactivity distribution of 99m Tc-methylene diphosphonate (MDP) and 99m TcHydroxymethylene diphosphonate (HMDP). In Japan, 99m Tc-MDP and 99m Tc-HMDP have been used in bone scintigraphy as radiopharmaceuticals and there are two methods of on-site preparation of kits and ready-to-use radiopharmaceuticals. Two manufacturers have provided radiopharmaceuticals for bone scintigraphy. One has 555 and 740 MBq and the other has 370, 555, 740 and 925 MBq as assay radioactivity for one patient. For the present survey, information regarding whether kits were prepared on-site or ready-to-use radiopharmaceuticals was not obtained. The administered radioactivity distribution of 99m Tc-MDP and 99m Tc-HMDP was almost the same, and, the numbers of 740 MBq in both agents were the highest because administration of radioactivity of 555-740 MBq is recommended by the package insert, texts and guidelines as a standard administration activity in Japan. The percentages of response rates in the range of 740 MBq ± 5 % of 99m Tc-MDP and 99m Tc-HMDP were 30 and 31 %, respectively. The latter is around 930 MBq because the dose of 930 MBq corresponds to the case of administration of 740 MBq (assay activity at 12 am) at 10 am. Two radiopharmaceuticals for bone scintigraphy are recommended to be scanned from 2 to 3 h after administration. This may reflect the reality that many nuclear facilities are imaging at 1 pm after administration at 10 am using an assay radioactivity of 740 MBq (ready-to-use radiopharmaceuticals). Figure 2 shows the distribution of 99m Tc-hexamethylpropylene amine oxime (HM-PAO) and 99m Tc-ethyl cysteinate dimer (ECD). In Japan, 99m Tc-HM-PAO and 99m Tc-ECD are used for cerebral blood flow scintigraphy of 99m Tc agents as a radiopharmaceutical. 99m Tc-HM-PAO is used only by on-site preparation of kits and 99m Tc-ECD either by on-site preparation of kits or ready-to-use Figure 3 shows the results of the distribution of N-isopropyl-p-[
123 I]iodoamphetamine (IMP). In Japan, for cerebral blood flow scintigraphy 123 I-IMP is provided by only delivery. 123 I-IMP has more kinds of assay radioactivities than other radiopharmaceuticals. One manufacturer has 111, 148, 167, 185 and 222 MBq and another has 111, 167 and 222 MBq as assay radioactivity for one patient. In addition, for 123 I-IMP, a wide range of administration doses of 111-222 MBq is recommended by the package insert, texts and guidelines as a standard administration dose. In particular, a wide range of administration radioactivity (37-222 MBq) is recommended in the package insert. Thus, the distribution of radioactivity of 123 I-IMP is scattered, which may reflect the various uses to which it is put at individual facilities. The response rate in the range of 111 MBq ± 5 % of 123 I-IMP was 7 %. Figure 4 shows the distribution of 99m Tc-Tetrofosmin and 99m Tc-hexakis-2-methoxyisobutylisonitrile (MIBI). In Japan, 99m Tc-Tetrofosmin and 99m Tc-MIBI have been used for myocardial perfusion scintigraphy as 99m Tc agents, and, Tl-Cl. Note: They are arranged in decreasing order to separate the nuclear medicine facilities with more from those with less radioactivity. Number responding was 384 F-FDG. Note: They are arranged in decreasing order to separate the nuclear medicine facility with more from those with less radioactivity. Numbers of delivery and in-house-produced were 132 and 73, respectively both agents have two methods of on-site preparation of kits and ready-to-use radiopharmaceuticals.
99m Tc-Tetrofosmin has 296, 592 and 740 MBq and 99m Tc-MIBI has 370, 600 and 740 MBq for one patient as the assay radioactivity. The response of around 740 MBq was the most common because an administration dose of 370-740 MBq is recommended by the package insert, texts and guidelines as a standard administration dose. The response rates in the range of 740 MBq ± 5 % of 99m Tc-Tetrofosmin and 99m Tc-MIBI were 37 and 30 %, respectively. Figure 5 shows the distribution of 201 Tl-Cl. In Japan, 201 Tl-Cl for myocardial perfusion scintigraphy has been made available only by delivery. The assay radioactivities of 201 Tl-Cl are 74, 11, 148 MBq for one patient provided by two manufacturers. The responses of 111 and 180 MBq were the most common. In Japan the manufacturers usually provide 201 Tl-Cl to the nuclear medicine facility within 2 days before the assay date; therefore, 180 MBq corresponds to the radioactivity 2 days before the assay radioactivity 111 MBq. The administration radioactivity of around 74-111 MBq is recommended by the package insert, texts and guidelines as a standard administration activity for 201 Tl-Cl. This study indicated that many nuclear medicine facilities administered the assay radioactivity 111 MBq for one patient in Japan (actual administered radioactivity is 180 MBq). The response rate in the range of 180 MBq ± 5 % of 201 Tl-Cl was 43 %. The distribution of administered radioactivity for 18 F-FDG oncology PET is shown in Fig. 6 and the responses of 185 MBq were the greatest. In Japan, nuclear medicine facilities have two methods, in-housed-produced and delivery for 18 F-FDG oncology PET. Provided manufacture of 18 F-FDG is one and it has an assay radioactivity of only 185 MBq for one patient. For these reasons, it is presumed that the responses of 185 MBq were diverse. The response rate in the range of 185 MBq ± 5 % of 18 F-FDG in-housed-produced and delivery were 19 and 27 %, respectively. In addition, the administered radioactivity per body weight (MBq/kg) was also investigated (Fig. 7) . However, whether in-housed-produced or delivery was not distinguished by the survey items. An administered radioactivity per body weight of 2-5 MBq/kg (three dimensional collection) is recommended by the guidelines [29] and it was found that most of the facilities administered within the recommended radioactivity doses per body weight. Furthermore, the numbers of responses of 3.0, 3.7 and 4.0 MBq/kg were the highest, and the administered radioactivity dose per body weight was considered is be determined in accordance with the guidelines.
This survey reveals that many nuclear facilities determined the administered radioactivity dose according to the package insert, texts and guidelines.
Comparison with EU and North America
Basically DRLs are determined based on 75th percentile of the survey results. To compare the administered radioactivity between Japan and EU, a summary of Japanese and EU DRLs for diagnostic nuclear medicine is shown in Table 2 following a list of the EU DRLs [9] . Many DRL doses of radiopharmaceuticals: bone scintigraphy ( 99m Tc-MDP and 99m Tc-HMDP), cerebral blood flow scintigraphy ( 99m Tc-HM-PAO) and myocardial perfusion scintigraphy ( 99m Tc-Tetrofosmin and 99m Tc-MIBI), etc. were within the range of the EU DRLs. Concerning 201 Tl-Cl (myocardial perfusion scintigraphy), Japan DRL 180 MBq exceeds the range of the EU DRL (75-150 MBq). For 99m Tc-pertechnetate (thyroid scintigraphy), Japan DRL 300 MBq exceeded the range of the EU DRLs (75-222 MBq). However, in the 18 F-FDG for oncology PET and 123 I-NaI for thyroid scintigraphy, Japan DRLs were at the lowest level in the range of the EU DRLs. These variations reflect the situation of each country, and so it is not considered that Japan DRLs are particularly high as compared with those of EU. Next, the results of this study were compared with SNMMI standard administered radioactivity in representative diagnostic nuclear medicine procedures: the upper limit of SNMMI standard administration radioactivity (bone scintigraphy: 1110 MBq [30] housed-produced and delivery: 100 %), respectively. Almost none of the administered radioactivity doses in Japan exceeded the upper limit of SNMMI standard administration radioactivity except for 201
Tl-Cl for myocardial perfusion. In 18 F-FDG for oncology PET, none of the doses at any of the facilities (100 %) exceeded the lower limit of SNMMI recommended administered radioactivity.
Convergence rate of the administered radioactivity, and the role of academic societies and experts Table 3 shows the percentage of facilities that were within the range (25, 30 and 50 %) from the median of representative diagnostic nuclear medicine examinations in Japan. More than half of the facilities were within the range of 25 %. In addition, more than 90 % of the facilities were within the range of 50 %. In particular, the percentage of facilities was greater than 95 % in the range of 50 % in representative diagnostic nuclear medicine procedures except for the 99m Tc-Tetrofosmin (myocardial perfusion scintigraphy) and 201 Tl-Cl (myocardial perfusion scintigraphy). Our findings indicate that the administered radioactivity for diagnostic nuclear medicine has been in convergence zones in Japan.
Essentially, optimization of the dose by DRL is performed at each facility, and is believed to lead to optimization in the whole country or region. However, nuclear medicine facilities have a strong tendency to adhere to the texts and guidelines in Japan. Therefore, in the optimization of radiopharmaceutical doses in Japan, a greater role of societies and organizations or experts is needed. As the finding of this study shows and the current state of Japan, to optimize radiopharmaceutical doses, Achievable Doses (ADs) [10, 12] might be useful, too.
Development of Japan DRLs
Based on the results of this study, a draft of Japan DRLs was prepared by the JSNM radiological protection committee.
Subsequently, it was approved by the JSNM board of directors, board of directors of the societies and organizations that performed the collaboration investigation, J-RIME general meeting and J-RIME constituent bodies, respectively, and Japan DRLs were officially published on June 7, 2015 [34] .
Limitation
Although the actual administered radioactivity doses to a standard body weight patient were obtained, the weight of the patients was not specified. It is necessary to pay attention to determine doses for DRLs when the standard body weight is different, because it is likely that the standard weight differs between Westerners and Asians.
Conclusions
For the first time a nationwide survey by nuclear medicinerelated societies and organizations for the development of the Japanese DRLs of nuclear medicine was conducted in Japan. This study demonstrated that the administered radioactivity in diagnostic nuclear medicine in Japan has been in the convergence zone. Nuclear medicine facilities in Japan show a strong tendency to adhere to the package insert, texts and guidelines. Furthermore, the Japan administered radioactivities were within the range of variation of the EU and the SNMMI administration radioactivities. Whether nuclear facilities can optimize the dose, or whether this is required, depends on the role of the academic societies and experts.
